舒普深腹腔注药治疗严重肝病腹水感染的临床疗效  

Clinical efficacy of Sulperazon intraperitoneal injection therapy in the treatment of severe liver ascites infection

作　　者：杨发成[1] 

机构地区：[1]四川省广安市人民医院感染科,四川广安638001

出　　处：《胃肠病学和肝病学杂志》2016年第2期181-183,共3页Chinese Journal of Gastroenterology and Hepatology

摘　　要：目的探讨严重肝病腹水感染采用舒普深腹腔注药治疗的临床疗效及对肝肾功能的影响。方法随机选取2012年3月-2014年3月四川省广安市人民医院收治的44例严重肝病腹水感染患者,依据随机数字表法将患者分为研究组和对照组,每组各22例。研究组患者给予舒普深腹腔注药治疗,对照组患者给予菌必治静脉滴注治疗。结果研究组患者的治愈率和总有效率54.5%(12/22)和95.5%(21/22)均显著高于对照组36.4%(8/22)和68.2%(15/22)(P<0.05);研究组患者的完全好转时长显著短于对照组(P<0.05),死亡率4.5%(1/22)显著低于对照组18.2%(4/22)(P<0.05)。结论严重肝病腹水感染采用舒普深腹腔注药治疗的临床疗效显著,且不会影响患者的肝肾功能。Objective To investigate the clinical efficacy and effect on liver and kidney function of Sulperazon intra- peritoneal injection therapy in the treatment of severe liver ascites infection. Methods Forty-four cases of severe liver ascites infected patients in People＇s Hospital of Guang＇ an City from Mar. 2012 to Mar. 2014 were selected randomly. These patients were divided into study group （n = 22） and control group （n = 22） by random sampling method. The study group was given Sulperazon intraperitoneal injection treatment, while the control group was given intravenous Ceftriaxone treatment. Results The cure rate and total treatment effective rate of study group [54.5% （12/22）, 95.5% （21/22） ] were significantly higher than the control group [36.4% （8/22）, 68.2% （15/22） ] （P 〈0.05） ; the better long when complete was significantly shorter （P 〈 0.05）, the mortality rate [ 4.5% （1/22） ] was significantly lower than the control group [ 18.2 % （4/22） ] （P 〈 0.05）. Conclusion The clinical efficacy of Sulperazon intraperitoneal injection therapy is significant in the treatment of severe liver ascites infection, and it has no effect on the patient＇ s liver and kidney function.

关 键 词：严重肝病腹水感染 舒普深腹腔注药 临床疗效 肝肾功能 影响 

分 类 号：R512.62[医药卫生—内科学]